379 related articles for article (PubMed ID: 36695751)
21. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
22. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
23. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
Husein-ElAhmed H; Husein-ElAhmed S
J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
[TBL] [Abstract][Full Text] [Related]
26. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
27. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
29. European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L; Arenbergerova M; Grimalt R; Ioannides D; Katoulis AC; Lazaridou E; Olszewska M; Ovcharenko YS; Piraccini BM; Prohic A; Rakowska A; Reygagne P; Richard MA; Soares RO; Starace M; Vañó-Galvan S; Waskiel-Burnat A
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):687-694. PubMed ID: 38169088
[TBL] [Abstract][Full Text] [Related]
30. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
31. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
Slomski A
JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
[No Abstract] [Full Text] [Related]
32. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors for alopecia areata: a systematic review and meta-analysis.
Phan K; Sebaratnam DF
J Eur Acad Dermatol Venereol; 2019 May; 33(5):850-856. PubMed ID: 30762909
[TBL] [Abstract][Full Text] [Related]
34. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
35. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
[TBL] [Abstract][Full Text] [Related]
36. Olumiant
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2022; 20(6):452-455. PubMed ID: 36537681
[TBL] [Abstract][Full Text] [Related]
37. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
38. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
39. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]